Data at The ECTRIMS Meetings will be presented from across Biogen Idec’s portfolio, including:
Investigational medicines:
PLEGRIDY(pegylated
interferon beta-1a): a potential new molecular entity for relapsing
forms of MS in which interferon beta-1a is pegylated to extend its
half-life and prolong its exposure in the body. Pegylation offers a
less-frequent dosing schedule.
DACLIZUMAB HIGH-YIELD PROCESS
(DAC HYP): is being developed as a once-monthly subcutaneous injection.
DAC HYP is believed to target the activated immune cells that can play a
key role in MS without causing general immune cell depletion. DAC HYP
is being developed under a collaboration agreement with AbbVie, Inc.
Anti-LINGO-1 (BIIB033): is the first candidate being investigated for its potential to repair neurons damaged by MS.
Approved medicines:
TYSABRI® (natalizumab): offers established efficacy that has been proven to reduce relapses and slow disability progression.
TECFIDERA®
(dimethyl fumarate): an oral treatment for relapsing forms of MS,
including relapsing-remitting MS (RRMS), which has been clinically
proven to significantly reduce important measures of disease activity
with a favorable safety/tolerability profile. TECFIDERA is currently
approved in the United States, Canada and Australia.
FAMPYRA®
(prolonged-release fampridine tablets): the first approved treatment to
address the unmet medical need of walking improvement in MS patients,
demonstrating efficacy in patients with all MS types. Approved in the
European Union.
The titles of key Biogen Idec abstracts are as follows:
TYSABRI:
October 3
Poster #519: Effects of natalizumab treatment on freedom from disease activity by baseline characteristics in AFFIRM
Poster
#524: Natalizumab reduces the disabling amplitude of multiple sclerosis
relapses and improves post-relapse residual disability
October 4
Poster
#1050: Disease activity and disability progression decrease beyond two
years on natalizumab in relapsing multiple sclerosis patients in the
TYSABRI® (natalizumab) Observational Programme
TECFIDERA:
October 3
Poster
#538: 4-year follow-up of oral BG-12 (dimethyl fumarate) treatment in
relapsing remitting multiple sclerosis (RRMS): integrated clinical
efficacy data from the DEFINE, CONFIRM, and ENDORSE studies
October 4
Poster
#1004: 4-year follow-up of oral BG-12 (dimethyl fumarate) treatment in
relapsing remitting multiple sclerosis (RRMS): integrated magnetic
resonance imaging (MRI) outcomes from DEFINE, CONFIRM, and ENDORSE
Poster
#1127: Interim analysis of quality of life in patients with relapsing
remitting multiple sclerosis treated with BG-12 (dimethyl fumarate) in
the ENDORSE study
Poster #996: Safety profile of BG-12 (dimethyl
fumarate) in relapsing remitting multiple sclerosis: long-term interim
results from the ENDORSE extension study
Poster #990: Effect of
BG-12 (dimethyl fumarate) in newly diagnosed relapsing remitting
multiple sclerosis (RRMS) patients from the DEFINE and CONFIRM studies
Poster #1100: Dimethyl fumarate and monomethyl fumarate are distinguished by non-overlapping pharmacodynamic effects in vivo
FAMPYRA:
October 3
Poster
#665: Long-term prolonged-release fampridine treatment and
health-related quality of life outcomes: nine-month interim analysis of
the ENABLE study
Poster #658: Health-related quality of life
outcomes following long-term treatment with prolonged-release
fampridine: impact on psychological outcomes in the ENABLE study
October 4
Poster
#1128: Changes in physical functioning and activity following long-term
treatment with prolonged-release fampridine in the ENABLE study
PLEGRIDY:
October 3
Poster
#514: Peginterferon beta-1a provides improvements in clinical and
radiological disease activity in relapsing-remitting multiple sclerosis:
year 1 findings from the phase 3 ADVANCE study
October 4
Poster
#989: Magnetic resonance imaging results from the first year of the
ADVANCE study, a pivotal phase 3 trial of peginterferon beta-1a in
patients with relapsing-remitting multiple sclerosis
Anti-LINGO-1:
October 3
Poster
#545: The use of magnetic resonance imaging to monitor the safety of
anti-LINGO-1: findings from phase I studies in healthy volunteers and
subjects with multiple sclerosis
Poster #378: Blocking LINGO1 promotes axonal regeneration in the rat optic nerve crush model
DACLIZUMAB HYP:
October 4
Poster #977: Reduction in brain atrophy with extended daclizumab HYP treatment: results of SELECT and the SELECT extension study
Poster
#864: Evaluation of immunogenicity in multiple sclerosis patients
continuously treated with daclizumab-HYP during the SELECT and SELECTION
clinical trials.
